Bortezomib, a first-in-class proteasome inhibitor, remains a foundational therapy in the management of multiple myeloma and mantle cell lymphoma (MCL). Its mechanism of action—selectively inhibiting the 26S proteasome—disrupts protein degradation pathways in malignant plasma cells, leading to apoptosis and tumor suppression. As a result, Bortezomib plays a critical role in both frontline and relapsed/refractory settings, often in combination regimens with immunomodulators, corticosteroids, and chemotherapeutics. For API manufacturers, exporters, and procurement professionals, identifying reliable Bortezomib buyers is a strategic imperative. This guide provides a comprehensive overview of the global Bortezomib buyers landscape, including trade data insights, key buyer categories, regional demand patterns, regulatory considerations, and actionable strategies for connecting with verified…